| Over a month ago | ||||
As at December 31, 2019,… As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2M, which the company believes, together with the net cash proceeds of approximately $8M received from the January 2020 offering and exercises of warrants in the first quarter of 2020, are sufficient to fund planned operations into the fourth quarter of 2020. | ||||
Reports Q4 revenue… Reports Q4 revenue approximately $1.2M, consensus $920,000. | ||||
| Over a quarter ago | ||||
Titan Pharmaceuticals… Titan Pharmaceuticals reports that, since January 1, it has received proceeds of approximately $5.9M as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants. The Class B Warrants were issued in connection with the company's public offering completed in October 2019. The Class B Warrants have an exercise price of 22.5c and are set to expire in October 2024. Approximately 14.1 Class B Warrants remain outstanding. | ||||
Notable call activity was… Notable call activity was cited Tuesday in Titan Pharmaceuticals (TTNP). | ||||
Heavy call volume in… Heavy call volume in low-dollar biotech Titan Pharmaceuticals. Shares up 8c to 49c this morning with 1700 calls trading early, vs 4 puts, and most of the flow in the Aug 2.5 calls, bought for a nickel nearly 1500x. Appears to add to 8100 already open at the strike. | ||||
Titan Pharmaceuticals… Titan Pharmaceuticals announced that it has signed an agreement for Probuphine implant to be included on the Federal Supply Schedule, providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for Opioid Use Disorder in eligible patients. The final FSS contract is effective January 15, 2020 and has a five-year term. The FSS contract will extend access to Probuphine to over nine million VA beneficiaries and others within the federal system. | |
A post to a website of… A post to a website of the U.S. General Services Administration shows that a Veterans Affairs Department contract was awarded to Titan Pharmaceuticals on December 26, 2019. The webpage, which was published today, lists a "Base and All Options Value" for the contract of "$0.00." Reference Link | |
Reports Q3 revenue… Reports Q3 revenue $900,000, consensus $700,000. As of September 30, Titan had cash and cash equivalents of approximately $0.9M. Titan believes that its cash and cash equivalents as of September 30, along with the approximately $8.1M of net cash proceeds from the public offering completed in October, will be sufficient to fund its operations into the third quarter of 2020. | |
Maxim analyst Jason… Maxim analyst Jason McCarthy upgraded Titan Pharmaceuticals to Buy from Hold with a $1 price target. The analyst cites the company's removed financing overhang after its capital raise, saying he is also positive on the potential of Titan's relaunch of probuphine for the treatment of opioid use disorder. | |
Maxim analyst Jason… Maxim analyst Jason McCarthy upgraded Titan Pharmaceuticals to Buy from Hold with a price target of $1.00. |